Latest News

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.

Feasibility of Clinical Production of Autologous NKG2D CAR-T

Feasibility of Clinical Production of Autologous NKG2D CAR-T

The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.

A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities

A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities

In a small group of head and neck cancer patients, biweekly doses of cetuximab in the maintenance setting appeared to be more tolerable than weekly doses.

PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC

PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC

The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.

S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease

S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease

Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.

High-Dose Busulfan Plus Melphalan Consolidation Therapy May Improve Outcomes in Ewing Sarcoma

High-Dose Busulfan Plus Melphalan Consolidation Therapy May Improve Outcomes in Ewing Sarcoma

Previous studies have suggested that high-dose therapy with busulfan plus melphalan may confer a benefit to patients with Ewing sarcoma compared with conventional chemotherapy.

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.

All CAR Signaling Domains in Lymphoma Are Not Created Equal

All CAR Signaling Domains in Lymphoma Are Not Created Equal

Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.

Checkpoint Blockade Demonstrates Antitumor Activity in HIV-Associated Kaposi Sarcoma

Checkpoint Blockade Demonstrates Antitumor Activity in HIV-Associated Kaposi Sarcoma

One patient achieved complete remission in the trial, while 5 other patients experienced partial remission.

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs